A Phase 3 interventional study of Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-21.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 11th largest by enrollment of the 125 interventional ones that give a count, is the only one that started in 1998, is one of 34 in phase 3, and was the 91st registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 631 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 11th largest by enrollment of the 111 interventional ones that give a count, is the only one that started in 1998, is one of 50 in phase 3, and was the 70th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia. Information on the continued efficacy of aripiprazole was also gathered in this long-term trial (until 31 Dec 2012 or until aripiprazole was otherwise available through marketed means and/or reimbursed).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Complete a Prior Study: each patient must meet one of the following conditions for completion of the prior study:
A patient who was early-terminated from the study 31-97-301 or 31-98- 304-01 for either of the following two reasons is eligible to enter this open label study with no minimal required duration of prior double-blind participation:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
Drug: Aripiprazole
Also known as: Abilify
Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Week
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Change From Baseline in PANSS Positive Sub-scale Score by Week
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Change From Baseline in PANSS Negative Sub-scale Score by Week
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) by Week
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Clinical Global Impression of Improvement (CGI-I) by Week
The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. The questionnaire includes questions on the following symptoms. 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The usual cut-off points are: 0 to 6 = normal/ symptom absent, 7 to 19 = mild depression, 20 to 34 = moderate depression, \>34 = severe depression.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score by Week
The SAS is composed of 10 items. This scale contains 10 items: Gait, Arm dropping, Shoulder shaking, Elbow rigidity, Wrist rigidity, Head rotation, Glabella Tap, Tremor, Salivation, Akathisia. Grade of severity of each item is rated using a 5-point scale, 1 (normal) and 5 (most severe). The total score ranges from 10 to 50. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Change From Baseline in Barnes Akathisia Rating Scale Score (BARS) Total Score by Week
BARS consisted of 4 items: objective observation of akathisia by study physician, subjective feelings of restlessness by participant, participant distress due to akathisia, global evaluation of akathisia. The first 3 items were rated on a 4-point scale: 0 = absence of symptoms to 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). Participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were elicited by direct questioning. The BARS Global Score was derived from the global clinical assessment of akathisia from the BARS panel. Total score ranges from 0 to 14. Negative changes from baseline indicate improvement, with higher negative values indicating better improvement.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Mean Change From Baseline in Abnormal Involuntary Movement Scale Score (AIMS) Total Score by Week
The AIMS assessment consisted of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest (e.g., in the waiting room), and the study physician would make global judgments on the participant's dyskinesia's (items 8 through 10). For this scale, the participant was seated on a hard, firm chair. These items are rated on a five-point scale: 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). The total score ranges from 0 to 40. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Number of Participants With Adverse Events (AEs)
The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial.
Time frame: Baseline to Last Visit
Percentage of Participants With Vital Signs of Potential Clinical Relevance
The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Percentage of Participants With ECG Measurements of Potential Clinical Relevance
The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Percentage of Participants With Laboratory Values of Potential Clinical Relevance
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
This trial was conducted in 631 participants at 139 trial sites in 23 countries.
| Milestone | Aripiprazole |
|---|---|
| Started | 631 |
| Completed | 0 |
| Not completed | 631 |
| Withdrew: Lost to follow-up | 21 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 236 |
| Withdrew: Insufficient clinical response | 26 |
| Withdrew: Adverse event | 44 |
| Withdrew: Sponsor discontinued trial | 167 |
| Withdrew: Noncompliance | 27 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Met withdrawal criteria | 7 |
| Withdrew: Ae of worsening schizophrenia | 96 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 619) | -1.63 ± 7.92 |
| Week 2 (N= 595) | -3.19 ± 9.64 |
| Week 4 (N= 586) | -4.27 ± 10.90 |
| Week 6 (N= 573) | -4.93 ± 12.07 |
| Week 8 (N= 552) | -5.35 ± 13.03 |
| Week 12 (N= 532) | -5.47 ± 14.61 |
| Week 16 (N= 517) | -6.28 ± 14.44 |
| Week 24 (N= 489) | -6.78 ± 14.22 |
| Week 36 (N= 458) | -7.22 ± 14.17 |
| Week 48 (N= 426) | -8.07 ± 15.72 |
| Week 60 (N= 395) | -9.28 ± 14.71 |
| Week 72 (N= 382) | -9.81 ± 15.98 |
| Week 84 (N= 362) | -10.54 ± 15.92 |
| Week 96 (N= 340) | -10.68 ± 16.40 |
| Week 108 (N= 328) | -11.46 ± 16.56 |
| Week 120 (N= 316) | -11.43 ± 17.01 |
| Week 132 (N= 306) | -11.05 ± 17.37 |
| Week 144 (N= 288) | -11.70 ± 17.72 |
| Week 156 (N= 279) | -11.90 ± 17.47 |
| Week 168 (N= 272) | -11.69 ± 17.11 |
| Week 180 (N= 268) | -11.83 ± 17.41 |
| Week 192 (N= 255) | -11.46 ± 18.00 |
| Week 204 (N= 239) | -12.10 ± 17.72 |
| Week 216 (N= 238) | -11.54 ± 17.05 |
| Week 228 (N= 224) | -12.24 ± 17.53 |
| Week 240 (N= 183) | -12.14 ± 19.35 |
| Week 252 (N= 139) | -15.19 ± 18.61 |
| Week 264 (N= 83) | -22.16 ± 21.07 |
| Week 276 (N= 58) | -29.45 ± 20.33 |
| Week 288 (N= 56) | -28.79 ± 20.66 |
| Week 300 (N= 55) | -21.95 ± 19.91 |
| Week 312 (N= 37) | -25.35 ± 18.41 |
| Week 324 (N= 38) | -21.95 ± 17.45 |
| Week 336 (N= 28) | -24.86 ± 17.78 |
| Week 348 (N= 8) | -12.88 ± 14.71 |
| Week 360 (N= 10) | -17.70 ± 35.32 |
| Week 372 (N= 3) | -10.67 ± 4.16 |
| Week 384 (N= 5) | -4.60 ± 9.07 |
| Week 396 (N= 10) | -10.10 ± 12.67 |
| Week 408 (N= 9) | -5.56 ± 7.06 |
| Week 420 (N= 4) | -8.00 ± 2.83 |
| Week 432 (N= 3) | -13.67 ± 24.19 |
| Week 444 (N= 1) | -28.00 ± NA |
| Week 456 (N= 4) | -48.25 ± 32.12 |
| Week 468 (N= 2) | -36.00 ± 2.83 |
| Week 480 (N= 1) | -10.00 ± NA |
| Week 492 (N= 9) | -10.00 ± 13.52 |
| Week 504 (N= 2) | -9.50 ± 28.99 |
| Week 636 (N= 5) | -7.60 ± 22.35 |
| Week 648 (N= 2) | -10.00 ± 14.14 |
| Week 660 (N= 3) | -15.33 ± 19.66 |
| Week 672 (N= 1) | 1.00 ± NA |
| Week 696 (N= 1) | -7.00 ± NA |
| Last Visit (N= 629) | -2.30 ± 22.21 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 619) | -0.39 ± 2.51 |
| Week 2 (N= 595) | -0.81 ± 3.15 |
| Week 4 (N= 586) | -1.13 ± 3.47 |
| Week 6 (N= 573) | -1.23 ± 3.70 |
| Week 8 (N= 552) | -1.30 ± 3.97 |
| Week 12 (N= 533) | -1.24 ± 4.43 |
| Week 16 (N= 517) | -1.43 ± 4.20 |
| Week 24 (N= 489) | -1.54 ± 4.26 |
| Week 36 (N= 458) | -1.56 ± 4.20 |
| Week 48 (N= 426) | -1.73 ± 4.64 |
| Week 60 (N= 395) | -2.01 ± 4.32 |
| Week 72 (N= 382) | -2.08 ± 4.63 |
| Week 84 (N= 362) | -2.26 ± 4.65 |
| Week 96 (N= 340) | -2.26 ± 4.81 |
| Week 108 (N= 328) | -2.50 ± 4.76 |
| Week 120 (N= 316) | -2.45 ± 4.84 |
| Week 132 (N= 306) | -2.25 ± 5.02 |
| Week 144 (N= 289) | -2.49 ± 5.03 |
| Week 156 (N= 279) | -2.46 ± 4.87 |
| Week 168 (N= 272) | -2.35 ± 4.62 |
| Week 180 (N= 268) | -2.40 ± 4.78 |
| Week 192 (N= 255) | -2.22 ± 4.91 |
| Week 204 (N= 239) | -2.48 ± 4.86 |
| Week 216 (N= 238) | -2.21 ± 4.57 |
| Week 228 (N= 224) | -2.42 ± 4.51 |
| Week 240 (N= 183) | -2.10 ± 5.16 |
| Week 252 (N= 139) | -2.74 ± 4.81 |
| Week 264 (N= 83) | -4.24 ± 5.69 |
| Week 276 (N= 58) | -5.90 ± 5.80 |
| Week 288 (N= 56) | -6.30 ± 5.61 |
| Week 300 (N= 55) | -4.16 ± 5.54 |
| Week 312 (N= 37) | -5.27 ± 5.57 |
| Week 324 (N= 38) | -4.45 ± 5.64 |
| Week 336 (N= 28) | -5.46 ± 5.73 |
| Week 348 (N= 8) | -0.75 ± 1.04 |
| Week 360 (N= 10) | -3.80 ± 7.60 |
| Week 372 (N= 3) | -0.67 ± 0.58 |
| Week 384 (N= 5) | -0.80 ± 3.96 |
| Week 396 (N= 10) | -2.40 ± 3.63 |
| Week 408 (N= 9) | -0.89 ± 2.80 |
| Week 420 (N= 4) | -0.75 ± 1.50 |
| Week 432 (N= 3) | -4.67 ± 8.08 |
| Week 444 (N= 1) | -9.00 ± NA |
| Week 456 (N= 4) | -10.50 ± 5.97 |
| Week 468 (N= 2) | -6.50 ± 3.54 |
| Week 480 (N= 1) | -2.00 ± NA |
| Week 492 (N= 9) | -2.00 ± 2.65 |
| Week 504 (N= 2) | -2.50 ± 7.78 |
| Week 636 (N= 5) | -1.80 ± 4.02 |
| Week 648 (N= 2) | -4.50 ± 7.78 |
| Week 660 (N= 3) | -2.00 ± 2.65 |
| Week 672 (N= 1) | 1.00 ± NA |
| Week 696 (N= 1) | -1.00 ± NA |
| Last Visit (N= 629) | 0.23 ± 6.58 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 619) | -0.35 ± 2.18 |
| Week 2 (N= 595) | -0.82 ± 2.59 |
| Week 4 (N= 586) | -1.05 ± 3.04 |
| Week 6 (N= 573) | -1.24 ± 3.38 |
| Week 8 (N= 552) | -1.41 ± 3.54 |
| Week 12 (N= 532) | -1.54 ± 4.01 |
| Week 16 (N= 517) | -1.85 ± 4.12 |
| Week 24 (N= 489) | -2.02 ± 4.13 |
| Week 36 (N= 458) | -2.16 ± 4.41 |
| Week 48 (N= 426) | -2.43 ± 4.71 |
| Week 60 (N= 395) | -2.75 ± 4.38 |
| Week 72 (N= 382) | -2.94 ± 4.79 |
| Week 84 (N= 362) | -3.17 ± 4.87 |
| Week 96 (N= 340) | -3.22 ± 4.99 |
| Week 108 (N= 328) | -3.36 ± 4.99 |
| Week 120 (N= 316) | -3.37 ± 5.25 |
| Week 132 (N= 306) | -3.41 ± 5.29 |
| Week 144 (N= 288) | -3.58 ± 5.43 |
| Week 156 (N= 279) | -3.70 ± 5.27 |
| Week 168 (N= 272) | -3.68 ± 5.28 |
| Week 180 (N= 268) | -3.69 ± 5.21 |
| Week 192 (N= 255) | -3.65 ± 5.40 |
| Week 204 (N= 239) | -3.79 ± 5.37 |
| Week 216 (N= 238) | -3.74 ± 5.17 |
| Week 228 (N= 224) | -3.90 ± 5.38 |
| Week 240 (N= 183) | -4.09 ± 5.86 |
| Week 252 (N= 139) | -4.88 ± 5.69 |
| Week 264 (N= 83) | -6.87 ± 6.50 |
| Week 276 (N= 58) | -8.71 ± 6.57 |
| Week 288 (N= 56) | -8.32 ± 6.85 |
| Week 300 (N= 55) | -6.58 ± 6.42 |
| Week 312 (N= 37) | -7.51 ± 5.43 |
| Week 324 (N= 38) | -6.63 ± 4.44 |
| Week 336 (N= 28) | -7.43 ± 4.59 |
| Week 348 (N= 8) | -4.88 ± 5.89 |
| Week 360 (N= 10) | -5.60 ± 9.40 |
| Week 372 (N= 3) | -4.33 ± 1.53 |
| Week 384 (N= 5) | 0.00 ± 2.12 |
| Week 396 (N= 10) | -2.90 ± 3.67 |
| Week 408 (N= 9) | -1.22 ± 2.54 |
| Week 420 (N= 4) | -2.25 ± 2.22 |
| Week 432 (N= 3) | -2.67 ± 7.51 |
| Week 444 (N= 1) | -6.00 ± NA |
| Week 456 (N= 4) | -13.75 ± 9.95 |
| Week 468 (N= 2) | -9.00 ± 5.66 |
| Week 480 (N= 1) | -5.00 ± NA |
| Week 492 (N= 9) | -2.00 ± 3.61 |
| Week 504 (N= 2) | -1.50 ± 12.02 |
| Week 636 (N= 5) | -1.80 ± 5.85 |
| Week 648 (N= 2) | 0.00 ± 0.00 |
| Week 660 (N= 3) | -4.67 ± 6.66 |
| Week 672 (N= 1) | 1.00 ± NA |
| Week 696 (N= 1) | -3.00 ± NA |
| Last Visit (N= 629) | -1.34 ± 6.09 |
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 619) | -0.07 ± 0.49 |
| Week 2 (N= 595) | -0.13 ± 0.60 |
| Week 4 (N= 586) | -0.20 ± 0.67 |
| Week 6 (N= 573) | -0.23 ± 0.78 |
| Week 8 (N= 552) | -0.25 ± 0.79 |
| Week 12 (N= 533) | -0.25 ± 0.86 |
| Week 16 (N= 517) | -0.30 ± 0.86 |
| Week 24 (N= 489) | -0.31 ± 0.89 |
| Week 36 (N= 458) | -0.32 ± 0.95 |
| Week 48 (N= 426) | -0.38 ± 0.94 |
| Week 60 (N= 395) | -0.45 ± 0.92 |
| Week 72 (N= 382) | -0.45 ± 0.93 |
| Week 84 (N= 362) | -0.49 ± 0.95 |
| Week 96 (N= 340) | -0.48 ± 0.99 |
| Week 108 (N= 328) | -0.51 ± 0.95 |
| Week 120 (N= 316) | -0.53 ± 0.98 |
| Week 132 (N= 306) | -0.48 ± 1.03 |
| Week 144 (N= 290) | -0.52 ± 1.04 |
| Week 156 (N= 279) | -0.53 ± 1.00 |
| Week 168 (N= 272) | -0.53 ± 0.96 |
| Week 180 (N= 268) | -0.55 ± 0.98 |
| Week 192 (N= 255) | -0.54 ± 1.04 |
| Week 204 (N= 239) | -0.55 ± 1.01 |
| Week 216 (N= 238) | -0.53 ± 0.99 |
| Week 228 (N= 232) | -0.56 ± 1.00 |
| Week 240 (N= 216) | -0.56 ± 1.06 |
| Week 252 (N= 208) | -0.58 ± 0.96 |
| Week 264 (N= 194) | -0.58 ± 1.04 |
| Week 276 (N= 187) | -0.61 ± 1.01 |
| Week 288 (N= 177) | -0.64 ± 1.02 |
| Week 300 (N= 167) | -0.63 ± 0.99 |
| Week 312 (N= 145) | -0.57 ± 1.01 |
| Week 324 (N= 137) | -0.60 ± 0.99 |
| Week 336 (N= 121) | -0.59 ± 0.95 |
| Week 348 (N= 114) | -0.48 ± 0.97 |
| Week 360 (N= 105) | -0.54 ± 0.98 |
| Week 372 (N= 93) | -0.49 ± 0.94 |
| Week 384 (N= 91) | -0.51 ± 0.94 |
| Week 396 (N= 80) | -0.53 ± 1.06 |
| Week 408 (N= 69) | -0.62 ± 0.96 |
| Week 420 (N= 61) | -0.70 ± 1.07 |
| Week 432 (N= 58) | -0.69 ± 1.16 |
| Week 444 (N= 51) | -0.59 ± 0.96 |
| Week 456 (N= 48) | -0.65 ± 1.10 |
| Week 468 (N= 37) | -0.46 ± 1.04 |
| Week 480 (N= 33) | -0.42 ± 0.83 |
| Week 492 (N= 31) | -0.55 ± 0.99 |
| Week 504 (N= 21) | -0.57 ± 0.93 |
| Week 516 (N= 19) | -0.53 ± 0.84 |
| Week 528 (N= 19) | -0.47 ± 0.90 |
| Week 540 (N= 18) | -0.61 ± 0.70 |
| Week 552 (N= 18) | -0.56 ± 0.86 |
| Week 564 (N= 17) | -0.41 ± 0.87 |
| Week 576 (N= 17) | -0.35 ± 0.86 |
| Week 588 (N= 17) | -0.41 ± 0.87 |
| Week 600 (N= 16) | -0.44 ± 0.89 |
| Week 612 (N= 16) | -0.44 ± 0.89 |
| Week 624 (N= 16) | -0.50 ± 0.73 |
| Week 636 (N= 16) | -0.44 ± 0.89 |
| Week 648 (N= 10) | -0.70 ± 0.67 |
| Week 660 (N= 8) | -0.50 ± 0.53 |
| Week 672 (N= 3) | -0.67 ± 0.58 |
| Week 684 (N= 1) | -1.00 ± NA |
| Week 696 (N= 1) | -1.00 ± NA |
| Last Visit (N= 629) | -0.00 ± 1.31 |
The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 619) | 3.60 ± 0.93 |
| Week 2 (N= 595) | 3.42 ± 0.98 |
| Week 4 (N= 586) | 3.29 ± 1.02 |
| Week 6 (N= 573) | 3.21 ± 1.08 |
| Week 8 (N= 552) | 3.17 ± 1.10 |
| Week 12 (N= 533) | 3.16 ± 1.12 |
| Week 16 (N= 517) | 3.08 ± 1.18 |
| Week 24 (N= 489) | 3.03 ± 1.14 |
| Week 36 (N= 458) | 2.95 ± 1.14 |
| Week 48 (N= 426) | 2.88 ± 1.17 |
| Week 60 (N= 395) | 2.76 ± 1.14 |
| Week 72 (N= 382) | 2.73 ± 1.11 |
| Week 84 (N= 362) | 2.67 ± 1.11 |
| Week 96 (N= 340) | 2.67 ± 1.15 |
| Week 108 (N= 328) | 2.60 ± 1.12 |
| Week 120 (N= 316) | 2.58 ± 1.15 |
| Week 132 (N= 306) | 2.62 ± 1.17 |
| Week 144 (N= 290) | 2.59 ± 1.20 |
| Week 156 (N= 279) | 2.58 ± 1.16 |
| Week 168 (N= 272) | 2.57 ± 1.15 |
| Week 180 (N= 268) | 2.57 ± 1.16 |
| Week 192 (N= 255) | 2.59 ± 1.20 |
| Week 204 (N= 239) | 2.56 ± 1.16 |
| Week 216 (N= 238) | 2.56 ± 1.20 |
| Week 228 (N= 232) | 2.49 ± 1.17 |
| Week 240 (N= 216) | 2.48 ± 1.21 |
| Week 252 (N= 208) | 2.37 ± 1.13 |
| Week 264 (N= 194) | 2.14 ± 1.07 |
| Week 276 (N= 187) | 2.16 ± 1.03 |
| Week 288 (N= 177) | 2.26 ± 1.06 |
| Week 300 (N= 167) | 2.26 ± 1.16 |
| Week 312 (N= 145) | 2.18 ± 1.11 |
| Week 324 (N= 137) | 2.23 ± 1.05 |
| Week 336 (N= 121) | 2.03 ± 1.09 |
| Week 348 (N= 114) | 2.45 ± 1.00 |
| Week 360 (N= 105) | 2.53 ± 1.36 |
| Week 372 (N= 93) | 2.14 ± 1.07 |
| Week 384 (N= 91) | 2.50 ± 1.52 |
| Week 396 (N= 80) | 3.00 ± 1.63 |
| Week 408 (N= 69) | 2.50 ± 1.18 |
| Week 420 (N= 61) | 2.43 ± 1.40 |
| Week 432 (N= 58) | 2.00 ± 1.73 |
| Week 444 (N= 51) | 1.00 ± NA |
| Week 456 (N= 48) | 1.83 ± 0.75 |
| Week 468 (N= 37) | 2.00 ± 0.00 |
| Week 480 (N= 33) | 2.00 ± NA |
| Week 492 (N= 9) | 2.33 ± 1.32 |
| Week 504 (N= 2) | 2.50 ± 2.12 |
| Week 528 (N= 1) | 4.00 ± NA |
| Week 636 (N= 5) | 2.00 ± 0.00 |
| Week 648 (N= 2) | 1.50 ± 0.71 |
| Week 660 (N= 3) | 2.33 ± 1.15 |
| Week 672 (N= 3) | 1.00 ± NA |
| Week 696 (N= 1) | 1.00 ± NA |
| Last Visit (N= 629) | 3.35 ± 1.60 |
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. The questionnaire includes questions on the following symptoms. 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The usual cut-off points are: 0 to 6 = normal/ symptom absent, 7 to 19 = mild depression, 20 to 34 = moderate depression, \>34 = severe depression.
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 619) | -0.78 ± 3.62 |
| Week 2 (N= 595) | -1.13 ± 4.09 |
| Week 4 (N= 586) | -1.38 ± 4.73 |
| Week 6 (N= 572) | -1.54 ± 5.15 |
| Week 8 (N= 552) | -1.40 ± 4.98 |
| Week 12 (N= 533) | -1.31 ± 5.77 |
| Week 16 (N= 517) | -1.60 ± 5.41 |
| Week 24 (N= 489) | -1.61 ± 5.75 |
| Week 36 (N= 458) | -1.66 ± 5.75 |
| Week 48 (N= 425) | -1.75 ± 5.47 |
| Week 60 (N= 395) | -2.13 ± 5.41 |
| Week 72 (N= 382) | -2.21 ± 5.29 |
| Week 84 (N= 362) | -2.33 ± 5.51 |
| Week 96 (N= 339) | -2.26 ± 5.70 |
| Week 108 (N= 328) | -2.30 ± 5.68 |
| Week 120 (N= 316) | -2.40 ± 5.67 |
| Week 132 (N= 306) | -2.22 ± 5.85 |
| Week 144 (N= 291) | -2.47 ± 5.85 |
| Week 156 (N= 279) | -2.51 ± 5.64 |
| Week 168 (N= 272) | -2.51 ± 5.49 |
| Week 180 (N= 268) | -2.73 ± 5.67 |
| Week 192 (N= 255) | -2.53 ± 6.05 |
| Week 204 (N= 239) | -2.69 ± 6.20 |
| Week 216 (N= 238) | -2.50 ± 5.87 |
| Week 228 (N= 224) | -2.62 ± 5.82 |
| Week 240 (N= 183) | -2.92 ± 6.50 |
| Week 252 (N= 139) | -3.63 ± 6.53 |
| Week 264 (N= 83) | -5.52 ± 7.89 |
| Week 276 (N= 58) | -7.71 ± 8.88 |
| Week 288 (N= 56) | -7.57 ± 8.64 |
| Week 300 (N= 55) | -6.15 ± 7.52 |
| Week 312 (N= 37) | -7.24 ± 8.51 |
| Week 324 (N= 38) | -6.32 ± 8.76 |
| Week 336 (N= 28) | -7.21 ± 8.01 |
| Week 348 (N= 8) | -4.00 ± 7.45 |
| Week 360 (N= 10) | -2.80 ± 16.09 |
| Week 372 (N= 3) | -2.67 ± 2.08 |
| Week 384 (N= 5) | 0.00 ± 0.00 |
| Week 396 (N= 10) | -1.40 ± 2.95 |
| Week 408 (N= 9) | -1.89 ± 1.27 |
| Week 420 (N= 4) | 0.75 ± 4.11 |
| Week 432 (N= 3) | -2.33 ± 5.86 |
| Week 444 (N= 1) | -1.00 ± NA |
| Week 456 (N= 5) | -9.60 ± 8.85 |
| Week 468 (N= 2) | -3.00 ± 2.83 |
| Week 480 (N= 1) | 0.00 ± NA |
| Week 492 (N= 9) | -6.56 ± 8.44 |
| Week 504 (N= 2) | -13.50 ± 13.44 |
| Week 636 (N= 5) | 0.40 ± 3.36 |
| Week 648 (N= 2) | -1.00 ± 1.41 |
| Week 660 (N= 3) | -4.33 ± 2.31 |
| Week 672 (N= 1) | -2.00 ± NA |
| Week 696 (N= 1) | -1.00 ± NA |
| Last Visit (N= 629) | -0.31 ± 8.02 |
The SAS is composed of 10 items. This scale contains 10 items: Gait, Arm dropping, Shoulder shaking, Elbow rigidity, Wrist rigidity, Head rotation, Glabella Tap, Tremor, Salivation, Akathisia. Grade of severity of each item is rated using a 5-point scale, 1 (normal) and 5 (most severe). The total score ranges from 10 to 50. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 618) | -0.78 ± 3.05 |
| Week 2 (N= 594) | -1.01 ± 3.32 |
| Week 4 (N= 585) | -1.06 ± 3.68 |
| Week 6 (N= 572) | -1.14 ± 3.94 |
| Week 8 (N= 550) | -1.19 ± 4.00 |
| Week 12 (N= 532) | -1.28 ± 4.03 |
| Week 16 (N= 516) | -1.27 ± 4.18 |
| Week 24 (N= 488) | -1.24 ± 3.91 |
| Week 36 (N= 456) | -1.10 ± 3.79 |
| Week 48 (N= 426) | -1.33 ± 4.14 |
| Week 60 (N= 395) | -1.25 ± 3.89 |
| Week 72 (N= 382) | -1.36 ± 4.07 |
| Week 84 (N= 362) | -1.33 ± 4.16 |
| Week 96 (N= 338) | -1.24 ± 3.92 |
| Week 108 (N= 328) | -1.29 ± 3.83 |
| Week 120 (N= 316) | -1.22 ± 3.83 |
| Week 132 (N= 306) | -1.26 ± 3.88 |
| Week 144 (N= 289) | -1.26 ± 3.99 |
| Week 156 (N= 278) | -1.33 ± 4.04 |
| Week 168 (N= 272) | -1.31 ± 3.92 |
| Week 180 (N= 268) | -1.43 ± 4.08 |
| Week 192 (N= 255) | -1.46 ± 4.07 |
| Week 204 (N= 239) | -1.49 ± 4.16 |
| Week 216 (N= 238) | -1.39 ± 3.48 |
| Week 228 (N= 224) | -1.44 ± 3.55 |
| Week 240 (N= 183) | -1.68 ± 3.72 |
| Week 252 (N= 139) | -2.11 ± 4.16 |
| Week 264 (N= 83) | -2.89 ± 4.99 |
| Week 276 (N= 58) | -3.84 ± 5.64 |
| Week 288 (N= 56) | -3.88 ± 5.77 |
| Week 300 (N= 55) | -2.53 ± 4.55 |
| Week 312 (N= 37) | -2.30 ± 4.07 |
| Week 324 (N= 38) | -1.76 ± 4.10 |
| Week 336 (N= 28) | -1.64 ± 3.90 |
| Week 348 (N= 8) | -2.00 ± 2.78 |
| Week 360 (N= 9) | -0.44 ± 5.75 |
| Week 372 (N= 3) | -1.00 ± 0.00 |
| Week 384 (N= 5) | -0.20 ± 0.45 |
| Week 396 (N= 10) | -0.30 ± 1.16 |
| Week 408 (N= 9) | -0.89 ± 1.27 |
| Week 420 (N= 4) | -1.25 ± 1.50 |
| Week 432 (N= 3) | -1.00 ± 1.73 |
| Week 444 (N= 1) | 1.00 ± NA |
| Week 456 (N= 5) | -7.20 ± 8.87 |
| Week 468 (N= 2) | 0.00 ± 0.00 |
| Week 480 (N= 1) | -1.00 ± NA |
| Week 492 (N= 9) | -3.22 ± 5.33 |
| Week 504 (N= 2) | -3.00 ± 4.24 |
| Week 636 (N= 5) | -0.20 ± 0.45 |
| Week 648 (N= 2) | 0.00 ± 0.00 |
| Week 660 (N= 3) | -1.00 ± 1.00 |
| Week 672 (N= 1) | -3.00 ± NA |
| Week 696 (N= 1) | -7.00 ± NA |
| Last Visit (N= 628) | -1.36 ± 4.31 |
BARS consisted of 4 items: objective observation of akathisia by study physician, subjective feelings of restlessness by participant, participant distress due to akathisia, global evaluation of akathisia. The first 3 items were rated on a 4-point scale: 0 = absence of symptoms to 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). Participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were elicited by direct questioning. The BARS Global Score was derived from the global clinical assessment of akathisia from the BARS panel. Total score ranges from 0 to 14. Negative changes from baseline indicate improvement, with higher negative values indicating better improvement.
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 618) | -0.15 ± 0.67 |
| Week 2 (N= 595) | -0.20 ± 0.70 |
| Week 4 (N= 586) | -0.20 ± 0.74 |
| Week 6 (N= 572) | -0.23 ± 0.76 |
| Week 8 (N= 552) | -0.22 ± 0.79 |
| Week 12 (N= 533) | -0.22 ± 0.78 |
| Week 16 (N= 517) | -0.22 ± 0.77 |
| Week 24 (N= 489) | -0.22 ± 0.74 |
| Week 36 (N= 458) | -0.21 ± 0.75 |
| Week 48 (N= 425) | -0.20 ± 0.75 |
| Week 60 (N= 395) | -0.20 ± 0.70 |
| Week 72 (N= 382) | -0.19 ± 0.73 |
| Week 84 (N= 362) | -0.21 ± 0.74 |
| Week 96 (N= 340) | -0.21 ± 0.79 |
| Week 108 (N= 327) | -0.21 ± 0.77 |
| Week 120 (N= 316) | -0.20 ± 0.75 |
| Week 132 (N= 306) | -0.22 ± 0.76 |
| Week 144 (N= 291) | -0.22 ± 0.79 |
| Week 156 (N= 278) | -0.24 ± 0.79 |
| Week 168 (N= 272) | -0.22 ± 0.78 |
| Week 180 (N= 268) | -0.24 ± 0.81 |
| Week 192 (N= 255) | -0.29 ± 0.79 |
| Week 204 (N= 238) | -0.29 ± 0.80 |
| Week 216 (N= 237) | -0.26 ± 0.76 |
| Week 228 (N= 223) | -0.26 ± 0.78 |
| Week 240 (N= 183) | -0.24 ± 0.75 |
| Week 252 (N= 139) | -0.29 ± 0.81 |
| Week 264 (N= 83) | -0.51 ± 1.06 |
| Week 276 (N= 58) | -0.69 ± 1.16 |
| Week 288 (N= 56) | -0.64 ± 1.09 |
| Week 300 (N= 55) | -0.51 ± 0.96 |
| Week 312 (N= 37) | -0.35 ± 0.68 |
| Week 324 (N= 38) | -0.26 ± 0.60 |
| Week 336 (N= 28) | -0.29 ± 0.66 |
| Week 348 (N= 8) | -0.75 ± 1.04 |
| Week 360 (N= 9) | -0.22 ± 0.67 |
| Week 372 (N= 3) | 0.00 ± 0.00 |
| Week 384 (N= 5) | 0.00 ± 0.00 |
| Week 396 (N= 10) | -0.10 ± 0.32 |
| Week 408 (N= 9) | -0.33 ± 0.71 |
| Week 420 (N= 4) | -0.25 ± 0.50 |
| Week 432 (N= 3) | 0.00 ± 0.00 |
| Week 444 (N= 1) | 0.00 ± NA |
| Week 456 (N= 5) | -1.40 ± 1.67 |
| Week 468 (N= 2) | 0.00 ± 0.00 |
| Week 480 (N= 1) | 0.00 ± NA |
| Week 492 (N= 9) | -0.56 ± 1.01 |
| Week 504 (N= 2) | -1.50 ± 0.71 |
| Week 636 (N= 5) | -0.40 ± 0.89 |
| Week 648 (N= 2) | 0.00 ± 0.00 |
| Week 660 (N= 3) | -0.67 ± 1.15 |
| Week 672 (N= 1) | -4.00 ± NA |
| Week 696 (N= 1) | 0.00 ± NA |
| Last Visit (N= 629) | -0.26 ± 0.85 |
The AIMS assessment consisted of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest (e.g., in the waiting room), and the study physician would make global judgments on the participant's dyskinesia's (items 8 through 10). For this scale, the participant was seated on a hard, firm chair. These items are rated on a five-point scale: 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). The total score ranges from 0 to 40. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.
| Units on a scale | Aripiprazole |
|---|---|
| Week 1 (N= 619) | -0.21 ± 1.61 |
| Week 2 (N= 595) | -0.29 ± 1.77 |
| Week 4 (N= 586) | -0.28 ± 1.96 |
| Week 6 (N= 572) | -0.34 ± 2.25 |
| Week 8 (N= 552) | -0.34 ± 2.22 |
| Week 12 (N= 533) | -0.37 ± 2.26 |
| Week 16 (N= 517) | -0.39 ± 2.31 |
| Week 24 (N= 489) | -0.35 ± 2.08 |
| Week 36 (N= 458) | -0.21 ± 1.85 |
| Week 48 (N= 425) | -0.35 ± 2.17 |
| Week 60 (N= 395) | -0.33 ± 2.02 |
| Week 72 (N= 382) | -0.31 ± 2.10 |
| Week 84 (N= 362) | -0.31 ± 2.12 |
| Week 96 (N= 340) | -0.25 ± 1.84 |
| Week 108 (N= 328) | -0.27 ± 1.88 |
| Week 120 (N= 316) | -0.26 ± 1.85 |
| Week 132 (N= 306) | -0.26 ± 1.91 |
| Week 144 (N= 290) | -0.29 ± 1.97 |
| Week 156 (N= 279) | -0.31 ± 2.04 |
| Week 168 (N= 272) | -0.29 ± 1.87 |
| Week 180 (N= 268) | -0.34 ± 2.08 |
| Week 192 (N= 255) | -0.35 ± 2.08 |
| Week 204 (N= 239) | -0.30 ± 2.06 |
| Week 216 (N= 238) | -0.26 ± 1.50 |
| Week 228 (N= 224) | -0.31 ± 1.41 |
| Week 240 (N= 183) | -0.31 ± 1.44 |
| Week 252 (N= 139) | -0.40 ± 1.59 |
| Week 264 (N= 83) | -0.61 ± 1.95 |
| Week 276 (N= 58) | -0.76 ± 2.30 |
| Week 288 (N= 56) | -0.57 ± 2.72 |
| Week 300 (N= 55) | -0.18 ± 1.45 |
| Week 312 (N= 37) | -0.35 ± 0.68 |
| Week 324 (N= 38) | -0.32 ± 0.57 |
| Week 336 (N= 28) | -0.36 ± 0.56 |
| Week 348 (N= 8) | -0.50 ± 1.07 |
| Week 360 (N= 9) | -0.44 ± 0.73 |
| Week 372 (N= 3) | 0.00 ± 0.00 |
| Week 384 (N= 5) | 0.00 ± 0.00 |
| Week 396 (N= 10) | 0.00 ± 0.00 |
| Week 408 (N= 9) | 0.00 ± 0.00 |
| Week 420 (N= 4) | 0.00 ± 0.00 |
| Week 432 (N= 3) | 0.00 ± 0.00 |
| Week 444 (N= 1) | 0.00 ± NA |
| Week 456 (N= 5) | -1.00 ± 2.24 |
| Week 468 (N= 2) | 0.00 ± 0.00 |
| Week 480 (N= 1) | 0.00 ± NA |
| Week 492 (N= 9) | -0.44 ± 0.53 |
| Week 504 (N= 2) | -0.50 ± 0.71 |
| Week 636 (N= 5) | 0.20 ± 0.45 |
| Week 648 (N= 2) | 0.00 ± 0.00 |
| Week 660 (N= 3) | 0.00 ± 0.00 |
| Week 672 (N= 1) | 0.00 ± NA |
| Week 696 (N= 1) | 0.00 ± NA |
| Last Visit (N= 629) | -0.39 ± 2.36 |
The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial.
| Participants | Aripiprazole |
|---|---|
| Participants with serious TEAEs | 179 |
| Participants with severe TEAEs | 116 |
| Participants discontinued medication due to AE | 140 |
| Participants with TEAEs | 523 |
| Participants discontinued due to AEs or death | 140 |
The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.
| percentage of participants | Aripiprazole |
|---|---|
| Heart rate sitting increase ≥15 bpm (N=625) | 0.5 |
| Systolic sitting BP increase ≥20 mmHg (N=627) | 0.8 |
| Systolic sitting BP decrease ≥20 mmHg (N=627) | 1.3 |
| Diastolic sitting BP increase ≥15mmHg (N=627) | 3.0 |
| Weight gain ≥7% (N=622) | 38.9 |
| Weight loss ≥7% (N=622) | 23.6 |
The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.
| Percentage of participants | Aripiprazole |
|---|---|
| Tachycardia (N=612) | 0.8 |
| Bradycardia (N=612) | 7.5 |
| Sinus tachycardia (N=612) | 0.8 |
| Sinus bradycardia (N=612) | 7.4 |
| Ventricular premature beat (N=612) | 2.9 |
| Primary atrioventricular block (N=606) | 2.5 |
| Secondary atrioventricular block (N=612) | 0.2 |
| Left bundle branch block (N=612) | 0.2 |
| Right bundle branch block (N=612) | 16.0 |
| Pre-excitation syndrome (N=612) | 0.3 |
| Other intraventricular conduction block (N=611) | 1.8 |
| Acute infarction (N=612) | 0.2 |
| Old infarction (N=612) | 0.7 |
| QTcB (N=612) | 8.0 |
| QTcF (N=611) | 2.1 |
| QTcN (N=611) | 2.3 |
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.
| Percentage of participants | Aripiprazole |
|---|---|
| Alanine aminotransferase (IU/L) (N=626) | 1.1 |
| Aspartate aminotransferase (IU/L) (N=626) | 1.0 |
| Bilirubin (mg/dl) (high)(N=626) | 3.0 |
| Calcium (mg/dl) (low) (N=626) | 3.4 |
| Chloride (meq/l) (low) (N=626) | 0.5 |
| Chloride (meq/l) (high) (N=626) | 0.2 |
| Creatinine phosphokinase (IU/L) (N=626) | 14.9 |
| Creatinine (mg/dl) (N=617) | 0.5 |
| Glucose (mg/dl) (N=626) | 3.0 |
| Lactic dehydrogenase (IU/L) (N=626) | 0.2 |
| Potassium (meq/l) (low) (N=626) | 0.2 |
| Potassium (meq/l) (high) (N=626) | 5.3 |
| Sodium (meq/l) (low) (N=626) | 0.5 |
| Sodium (meq/l) (high) (N=626) | 0.2 |
| Urea nitrogen (mg/dl) (N=626) | 0.8 |
| Uric acid (mg/dl) (N=626) | 1.0 |
| Eosinophils (%) (N=624) | 3.2 |
| Hematocrit (%) (N=623) | 2.7 |
| Hemoglobin (g/dl) (N=625) | 2.4 |
| Platelet count (per cubic mm) (low) (N=625) | 0.2 |
| Platelet count (per cubic mm) (high) (N=625) | 0.3 |
| White blood count (thou/mcl) (low) (N=625) | 1.1 |
| White blood count (thou/mcl) (high) (N=625) | 3.8 |
| Glucose, urine (N=613) | 1.6 |
| Protein, urine (N=599) | 1.8 |
Collected over From the signing of the informed consent to 30 days after the end of study treatment. The investigator continued to report any significant follow-up information on the AE up to the time the event had been resolved.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole | — | 179/631 (28.4%) | 364/631 (57.7%) |
| Event | Aripiprazole |
|---|---|
| SchizophreniaPsychiatric disorders | 85/631 |
| Psychotic disorderPsychiatric disorders | 20/631 |
| Social stay hospitalisationSocial circumstances | 16/631 |
| AnxietyPsychiatric disorders | 10/631 |
| Suicidal attemptPsychiatric disorders | 6/631 |
| AgressionPsychiatric disorders | 4/631 |
| Completed suicidePsychiatric disorders | 4/631 |
| HallucinationPsychiatric disorders | 4/631 |
| OverdoseInjury, poisoning and procedural complications | 3/631 |
| Cardiac failureCardiac disorders | 2/631 |
| Event | Aripiprazole |
|---|---|
| InsomniaPsychiatric disorders | 118/631 |
| AkathisiaNervous system disorders | 84/631 |
| SchizophreniaPsychiatric disorders | 79/631 |
| AnxietyPsychiatric disorders | 73/631 |
| Weight increasedInvestigations | 56/631 |
| Extrapyramidal disorderNervous system disorders | 50/631 |
| TremorNervous system disorders | 50/631 |
| HeadacheNervous system disorders | 48/631 |
| InfluenzaInfections and infestations | 47/631 |
| Age, Continuous(Years) | Aripiprazole |
|---|---|
| Mean | 37.5 ± 11.0 |
| Sex: Female, Male(Participants) | Aripiprazole |
|---|---|
| Female | 264 |
| Male | 367 |
No study locations are listed for this record.
The record gives a start of Apr 1998, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →